Noronha V, et al. - In this phase III randomized trial, cisplatin (30 mg/m²) given once a week was assessed in comparison with cisplatin (100 mg/m²) given once every 3 weeks, both of which were administered concurrently with radiotherapy in patients with locally advanced head and neck squamous cell cancer (LAHNSCC). Once every 3 week cisplatin at 100 mg/m² was superior in terms of locoregional control (LRC), albeit more toxicity, compared to once a week cisplatin at 30 mg/m², and thus should remain the preferred chemoradiotherapy regimen for LAHNSCC in the adjuvant setting.